Codex DNA Announces Registration and Webcast Information for Upcoming R&D Webinar on March 29, 2022

Rhea-AI Summary

Codex DNA, Inc. (Nasdaq: DNAY) announced its first Investor R&D Webinar scheduled for March 29, 2022, at 8:00 a.m. PT. The webinar will highlight the company's R&D pipeline, particularly its proprietary Short Oligo Ligation Assembly (SOLA) enzymatic DNA synthesis technology. Attendees can pre-register via the provided link, and a live webcast will also be available on Codex DNA's Investor Relations website. As a leader in automated synthetic biology systems, Codex DNA aims to enhance the speed and accuracy of DNA and mRNA synthesis for various applications.

Positive

• Highlighting proprietary SOLA technology, potentially increasing interest from investors.
• Webinar could enhance investor engagement and transparency around R&D developments.

Negative

• None.

SAN DIEGO, March 03, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced details for its first Investor R&D Webinar. Management will describe the future promise of the company’s R&D pipeline, with a specific focus on its proprietary Short Oligo Ligation Assembly (SOLA) enzymatic DNA synthesis technology.

The webinar will be held virtually on March 29, 2022, beginning at 8:00 a.m. Pacific time / 11:00 a.m. Eastern time. The event should conclude at approximately 9:00 a.m. Pacific Time / 12:00 p.m. Eastern time.

Attendees are encouraged to pre-register for the webcast by following this link and completing the registration form. A link to the live webcast and related materials will also be available in the Investor Relations section of Codex DNA’s website, https://ir.codexdna.com. An archived replay of each webcast will be available following the event.

About Codex DNA
Codex DNA is empowering scientists with the ability to create novel, synthetic biology-enabled solutions for many of humanity’s greatest challenges. As inventors of the industry-standard Gibson Assembly^® method and the first commercial automated benchtop DNA and mRNA synthesis system, Codex DNA is enabling rapid, accurate, and reproducible writing of DNA and mRNA for numerous downstream markets. The company’s award-winning BioXp™ system consolidates, automates, and optimizes the entire synthesis, cloning, and amplification workflow. As a result, it delivers virtually error-free synthesis of DNA/RNA at scale within days and hours instead of weeks or months. Scientists around the world are using the technology in their own laboratories to accelerate the design-build-test paradigm for novel, high-value products for precision medicine, biologics drug discovery, vaccine and therapeutic development, genome editing, and cell and gene therapy. Codex DNA is a public company based in San Diego. For more information, visit codexdna.com.

Contact:
Richard Lepke
Director of Investor Relations
(619) 840-5392
RichardL@codexdna.com

FAQ

What is the date and time of Codex DNA's Investor R&D Webinar?

The Investor R&D Webinar is scheduled for March 29, 2022, at 8:00 a.m. Pacific Time.

What will be discussed in Codex DNA's R&D Webinar?

The webinar will focus on the company's R&D pipeline and its proprietary SOLA enzymatic DNA synthesis technology.

How can I register for Codex DNA's Investor Webinar?

Interested attendees can pre-register for the webinar through a link provided in the press release.

Where can I find the archived replay of the Codex DNA Webinar?

An archived replay of the webinar will be available on Codex DNA's Investor Relations website after the event.

What is the significance of the SOLA technology mentioned in the press release?

SOLA technology is a proprietary enzymatic DNA synthesis method that may enhance the efficiency and accuracy of DNA production, which is crucial for various scientific applications.